LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...

AstraZeneca said it is in China ‘for the long haul’ and outlined billions of pounds of investment in the US – but a new ...

AstraZeneca has put a £450m investment in Britain under review in a stand-off with ministers over state aid. The drugs giant ...

AstraZeneca’s new U.S. spending also leaves in doubt the pharmaceutical company’s plans to invest in a vaccine site in ...

AstraZeneca, the London-listed pharmaceutical company, has put its planned £650 million investment in UK vaccine research and ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

AstraZeneca's £450 million investment plan for vaccine R&D in the UK is under review as discussions on governmental ...

London-listed drugmaker AstraZeneca said its plan to invest 650 million pounds ($833.2 million) in Britain for vaccine ...

Stories on the discovery of vital fluid-transport systems in the human body are among the winners of the 2024 AAAS Kavli Science Journalism Awards. Winning journalists also did immersive stories on ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

The company said it aims to expand its U.S. presence by the end of 2026. The new spending will be for a research-and-development center in Cambridge, Mass.; manufacturing plants in Maryland and Texas, ...